Key facts
- SolasCure’s last known valuation is $57.0M (Jan 2021).
- It has raised $34.2M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Innovate UK, European Innovation Council, Texas Medical Center, SyndicateRoom, Development Bank of Wales — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for SolasCure
- ·The full record, as it builds
Funding rounds
No funding rounds for SolasCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SolasCure
Developer of hydrogel designed to treat patients with chronic wounds. The company's hydrogel contains a recombinant enzyme derived from maggots which aims to accelerate wound debridement, enabling patients to improve the outcomes in all settings and accelerate wound cleaning.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 22
- Website
- solascure.com/
- Ownership
- Privately Held (backing)
SolasCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SolasCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SolasCure in its N-PORT filings yet. We sweep new filings monthly.